Expression of p16 in non-small cell lung cancer and its prognostic significance: A meta-analysis of published literatures

Lung Cancer

Volumn 74, Issue 2, 2011, Pages 155-163

  Tong, Jinlong ^a,b   Sun, Xinchen ^b   Cheng, Hongyan ^b   Zhao, Di ^b   Ma, Jun ^b   Zhen, Qing ^b   Cao, Yuandong ^b   Zhu, Huiping ^b   Bai, Jianling ^c  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hazard ratio; Meta analysis; Non small cell lung cancer; P16; Prognosis

Indexed keywords

PROTEIN P16;

CANCER STAGING; CANCER SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053655289     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.019     Document Type: Review

References (55)

1. Jemal A., Siegel R., Ward E., Hao Y.P., Xu J.Q., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Naruke T., Tsuchiya R., Kondo H., Asamura H., Nakayama H. Implications of staging in lung cancer. Chest 1997, 112:242S-248S.
3. Goya T., Asamura H., Yoshimura H., Kato H., Shimokata K., Tsuchiya R., et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005, 50:227-234.
4. Naruke T., Tsuchiya R., Kondo H., Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001, 71:1759-1764.
5. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366(6456):704-707.
6. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
7. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756.
8. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
9. Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820-826.
10. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta analysis detected by a simple, graphical test. BMJ 1977, 315:629-634.
11. Kratzke R.A., Greatens T.M., Rubins J.B., Maddaus M.A., Niewoehner D.E., Niehans G.A., et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996, 56:3415-3420.
12. INK4 expression in non-small cell lung carcinoma. Cancer 1997, 80:389-395.
13. Volm M., Koomägi R., Mattern J. Prognostic value of p16INK4A expression in lung adenocarcinoma. Anticancer Res 1998, 18(4A):2309-2312.
14. Kawabuchib B., Moriyamas S., Hironaka M., Fujii M., Koike M., Moriyama H., et al. p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis. Int J Cancer 1999, 84:49-53.
15. Brambilla E., Moro D., Gazzeri S., Brambilla C. Alterations of expression of Rb, p16INK4A and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999, 188:351-360.
16. Hommura F., Dosaka-Akita H., Kinoshita I., Mishina T., Hiroumi H., Ogura S., et al. Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer 1999, 81:696-701.
17. Geradts J., Fong K.M., Zimmerman P.V., Maynard R., Minna J.D. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999, 5:791-800.
18. Huang C.I., Taki T., Higashiyama M., Kohno N. Miyake M.p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung. Br J Cancer 2000, 82:374-380.
19. Chen J.T., Chen Y.C., Chen C.Y., Wang Y.C. Loss of p16 and/or pRb protein expression in NSCLC. An immunohistochemical and prognostic study. Lung Cancer 2001, 31:163-170.
20. Jin M.L., Inoue S., Umemura T., Moriya J., Arakawa M., Nagashima K., et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001, 34:207-218.
21. Gessner C., Liebers U., Kuhn H., Stiehl P., Witt C., Schauer J., et al. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 2002, 19:134-140.
22. INK4A,pRB, and p53. J Surg Oncol 2002, 81:177-184.
23. González-Quevedo R., Iniesta P., Morán A., de Juan C., Sánchez-Pernaute A., Fernández C., et al. Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer. J Clin Oncol 2002, 20:254-262.
24. Cheng Y.L., Lee S.C., Harn H.J., Chen C.J., Chang Y.C., Chen J.C., et al. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer. Eur J Cardiothorac Surg 2003, 23:221-228.
25. Esposito V., Baldi A., Tonini G., Vincenzi B., Santini M., Ambrogi V., et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004, 57:58-63.
26. Esposito V., Baldi A., De Luca A., Tonini G., Vincenzi B., Santini D., et al. Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer. J Clin Pathol 2005, 58:734-739.
27. Yoo J.Y., Jung J.H., Lee M.A., Seo K.J., Shim B.Y., Kim S.H., et al. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007, 22:318-325.
28. Mohamed S., Yasufuku K., Hiroshima K., Nakajima T., Yoshida S., Suzuki M., et al. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer. Cancer 2007, 109:2506-2514.
29. Myong N.H. Cyclin D1 overexpression, p16 Loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell Lung carcinoma patients. Cancer Res Treat 2008, 40:45-52.
30. Tanaka R., Wang D., Morishita Y., Inadome Y., Minami Y., Iijima T., et al. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 2005, 103:608-615.
31. Zhu Z.H., Sun B.Y., Ma Y., Shao J.Y., Long H., Zhang X., et al. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol. 2009, 27:1091-1099.
32. Sakaguchi M., Fujii Y., Hirabayashi H., Yoon H.E., Komoto Y., Oue T., et al. Inverse correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996, 65:442-445.
33. Sirera R., Gil M., Blasco A., Cabrera A., Safont M.J., Iranzo V., et al. Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. Lung Cancer 2008, 61:104-108.
34. Osaki T., Oyama T., Inoue M., Gu C.D., Kodate M., Aikawa M., et al. Molecular biological markers and micrometastasis in resected non-small-cell lung cancer prognostic implications. Jpn J Thorac Cardiovasc Surg 2001, 49:545-551.
35. Beasley M.B., Lantuejoul S., Abbondanzo S., Chu W.S., Hasleton P.S., Travis W.D., et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003, 32:136-142.
36. Nakata S., Sugio K., Uramoto H., Oyama T., Hanagiri T., Morita M., et al. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 2006, 106:2190-2199.
37. Ghazizadeh M., Jin E., Shimizu H., Fujiwara M., Arai S., Ohaki Y., et al. Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas. Respiration 2005, 72:68-73.
38. Mishina T., Dosaka-Akita H., Kinoshita I., Hommura F., Morikawa T., Katoh H., et al. Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome. Br J Cancer 1999, 80:1289-1295.
39. Akin H., Yilmazbayhan D., Kiliçaslan Z., Dilege S., Doĝan O., Toker A., et al. Clinical significance of P16INK4A and retinoblastoma proteins in non-small cell lung carcinoma. Lung Cancer 2002, 38:253-260.
40. Groeger A.M., Caputi M., Esposito V., De Luca A., Bagella L., Pacilio C., et al. Independent prognostic role of p16 expression in lung cancer. J Thorac Cardiovasc Surg 1999, 118:529-535.
41. Igarashi T., Jiang S.X., Kameya T., Asamura H., Sato Y., Nagai K., et al. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol 2004, 17:1259-1267.
42. Abdulkader I., Sánchez L., Cameselle-Teijeiro J., Gude F., Chávez J.E., López-López R., et al. Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study. Oncol Rep 2005, 14:1527-1531.
43. Mohamed S., Yasufuku K., Nakajima T., Hiroshima K., Chiyo M., Yoshida S., et al. Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications. Eur Respir J 2009, 33:127-133.
44. Choi C.M., Seo K.W., Jang S.J., Oh Y.M., Shim T.S., Kim W.S., et al. Chromosomal instability is a risk factor for poor prognosis of adenocarcinoma of the lung: fluorescence in situ hybridization analysis of paraffin-embedded tissue from Korean patients. Lung Cancer 2009, 64:66-70.
45. Burke L., Flieder D.B., Guinee D.G., Brambilla E., Freedman A.N., Bennett W.P., et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005, 11:232-241.
46. Vonlanthen S., Heighway J., Kappeler A., Altermatt H.J., Borner M.M., Betticher D.C. p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. Int J Oncol 2000, 16:951-957.
47. Begg C., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
48. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995, 147:545-560.
49. Jang S.J. Cell cycle regulators as prognostic predictor of colorectal cancers. Korean J Gastroenterol 2004, 44:346-349.
50. Maelandsmo G.M., Berner J.M., Florenes V.A., et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas-relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1995, 72:393-398.
51. Wei G., Lonardo F., Ueda T., et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 1998, 80:199-204.
52. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E., et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998, 95:11891-11896.
53. Stewart L.A., Parmar M.K. Meta-analysis of the literature or of individual patient data: is there a difference?. Lancet 1993, 341:418-422.
54. Egger M., Zellweger-Zahner T., Schneider M., Junker C., Lengeler C., Antes G. Language bias in randomized controlled trials published in English and German. Lancet 1997, 350:326-329.
55. Earleywine M. The file drawer problem in the meta analysis of the subjective responses to alcohol. Am J Psychiatry 1993, 150:1435-1436.